EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

Jun 14 2012

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia. The data have been selected for oral presentation as part of the conference's "Late Breaking Novel Therapeutics" session, being held Wednesday, July 18, 2012 from 3:30 to 5 p.m. The data presentation will also be highlighted in an Alzheimer's Association news briefing at the conference on Wednesday, July 18, 2012 from 7:30 to 8:30 a.m.    

"These data mark an important step forward for EVP-6124 and the development of EnVivo's broad pipeline of CNS therapies," said Kees Been, president and chief executive officer of EnVivo Pharmaceuticals. "We look forward to sharing the data analysis with our colleagues and the scientific community at AAIC 2012."

EVP-6124 is a selective alpha-7 nicotinic agonist being studied in patients with mild to moderate Alzheimer's disease. The Phase 2b multi-center, dose ranging, placebo controlled, six-month study took place in the U.S. and Europe and was designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving the clinical condition of Alzheimer's disease patients. The primary endpoints of the trial were improvement in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog), a commonly used and established outcome measure, and the CDR-SB, a clinical rating scale that assesses patient function.